12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BBI608: Phase I/II data

Data from 26 evaluable patients in the dose-escalation Phase I portion of an open-label, North American Phase I/II trial showed that twice-daily oral 20-2,000 mg BBI608 produced a disease control rate (DCR) of 65%, including 17 cases of stable disease. The maximum tolerated dose (MTD) was not reached...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >